文献
401. US Food and Drug Administration. HIGHLIGHTS OF PRESCRIBING INFORMATION. ATACAND® (candesartan cilexetil) TABLETS.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020838s031lbl.pdf (Accessedn on Dec. 31, 2010)
402. Sakarcan A, Tenney F, Wilson JT, et al . The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001;
41: 742-749.
403. Wells T, Rippley R, Hogg R, et al. The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol 2001; 41: 1064-1074.
404. Hogg RJ, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr
Nephrol 2007; 22: 695-701.
405. Aronoff GR, Bennet WM, Berns JS, et al. 臨床透析編集委員会編集・翻訳．成人および小児における適正投薬法のガイドライン 腎不全時の薬物使用．
原書第5版．東京，日本メディカルセンター 2007: 242-273.
406. 平田純生，和泉智，古久保拓．透析患者への投薬ガイドブック・慢性腎臓病（CKD）の薬物治療．第2版．東京，じほう 2009.
407. Mclntyre CW, Owen PJ. Prescribing Drugs in Kidney Disease. Brenner BM edits. The Kidney. 8th ed. Philadelphia: Saunders Elsevier: 1930-1952.
408. Bennet WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis
1996; 28 (Suppl 1): S56-62.
409. Blantz RC. Acetaminophen: acute and chronic effects on renal function. Am J Kidney Dis 1996; 28 (Suppl 1): S3-6.
410. 日本腎臓病学会編. CKD診療ガイド 2009. 第2版．東京，東京医学社 2009: 83-113.
411. NSFとガドリニウム造影剤使用に関する合同委員会（日本医学放射線学会, 日本腎臓学会）．腎障害患者におけるガドリニウム造影剤使用に関するガイド
ライン. 2009 年2月．http://www.jsn.or.jp/guideline/
412. Hellden A, Odar-Cederlof I, Stahle L, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal
failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol Dial Transplant 2003; 18: 1135-1141.
413. St Peter WL, Redic-Kill KA, Halstenson CE. Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet
1992; 22: 169-210.
414. 斉藤篤. 腎障害時の化学療法. 外科治療 1997; 72: 1080-1085.
415. 日本感染症学会，日本化学療法学会編．抗菌薬使用のガイドライン．東京，協和企画 2005: 29-33.
416. 田中英高. 患者さんの背景・病態で考える 薬の選び方・使い方のエッセンス. 小児 起立性調節障害. 治療 2009; 91: 1418-1421.
417. Nelson textbook of pediatrics 19th edition 2011.
418. Badesch DB, Abman SH, Ahearn GS, et al. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice
guidelines. Medical therapy for pulmonary arterial hypertension. CHEST 2004; 126: 35S-62S.
419. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulomonary arterial hypertension. Updated ACCP evidence-based clinical practice
guidelines. CHEST 2007; 131: 1917-1928.
420. Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch
Cardiovasc Dis 2010; 103: 66-74.
421. Barst RJ, Ertel SI, Beghetti M, et al. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011;37: 665-677.
422. Rubin LJ, Rich S. Primary pulmonary hypertension. Lung biopsy in health and disease Vol.99. Marcel Dekker, Inc., New York 1997: 275-280.
423. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the national
institute of health registry on primary pulmonary hypertension. Am Rev Respir Dis 1989; 140: 1623-1630.
424. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
425. Roberts DH, Lepore JJ, Maroo A, et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary
hypertension. Chest 2001; 120: 1547-1555.
426. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response
study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: 384-389.
427. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin arterial hypertension: A randomized, double-blind, placebo
trial J Am Coll Cardiol 2002; 39: 1496-1502.
428. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost Therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
429. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcome in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-665.
430. Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664-670.
431. Beghtti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: Result
from the Europe an postmarketing surveillance program. Pediatr Res 2008; 64: 200-204.
432. Paul GA, Gibbs JSR, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.
Br J Clin Pharmacol 2005; 60: 107-112.
433. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, doubleblind, placebo-controlled, dose-ranging study of oral sildenafil citrare citrate in treatment-naïve
children with pulmonary hypertension. Circulation 2012; 125: 324-334.
434. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
435. Namachivayam P, Theilen U, Butt WW, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am
J Respir Crit Care Med; 2006: 1042-1047.
436. Nagendran J, Archer SL, Soliman D, et al. PDE5 is highly expressed in the hypertrophied human right ventricle and acute inhibition of PDE5 improves
contractility. Circulation 2007; 116: 238-248.
437. Sitbon O, Rubin LJ, Long WA, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation , 2005;
111: 3105-3111.
438. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task
force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-842.
439. 市田蕗子，佐地勉，梶野浩樹，他．平成21年度希少疾病サーベイランス調査結果．日小循誌 2010; 26: 348-350.
440. Heersche JH, Blom NA, Van de Heuvel F, et al. Implantable Cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the
Netherlands. Pacing Clin Electrophysiol 2009; 33: 179-185.
441. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic
cardiomyopathy. Heart 2007; 93: 708-710.
442. Fidler LM, Wilson GJ, Liu F, et al. Abnormal connexin43 in arrhythmogenic right ventricular cardiomyopathy caused by plakophilin-2 mutations. J Cell
Mol Med 2009; 13: 4219-4228.
443. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
444. Pasquali SK, Hall M, Slonim AD, et al. Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease.
Circ Cardiovasc Qual Outcomes 2008; 1: 74-83.
445. Venugopalan P, Agarwal AK, Worthing EA. Chronic cardiac failure in children due to dilated cardiomyopathy: diagnostic approach, pathophysiology
and management. Eur J Pediatr 2000; 159: 803-810.
446. Shaddy RE, Boucek MM, Hsu DT, et al. Pediatric Carvedilol Study Group, Carvedilol for children and adlescents with heart failure: a randomised
controlled trial. JAMA 2007; 298: 1171-1179.
447. Cochrane Database of Systematic Reviews. Beta-blockers for congestive heart failure in children. 1, 2009.
448. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart
failure: meta-analysis of individual data from 6500 patients in ramdomised trials. Lancet 1997; 350: 1417-1424.
449. 住友直方，岩本眞理，牛ノ濱大地，他．小児循環器学会「小児不整脈の診断・治療に関する検討委員会」．小児不整脈の診断・治療ガイドライン．日小循誌
2010, supple.
450. Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. Fund & Clin Pharmacol 2010;
24: 637-652.
451. Duncan WJ, Tyrrell MJ, Bharadwal BB. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children. Can J Cardiol 1991; 7: 81-86.
452. Klugman D, Berger JT, Sable CA, et al. Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol 2010; 31:
222-228.
453. Drucker NA, Drucker NA, Colan SD, et al. Gammaglobulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-257.
454. 日本小児循環器学会学術委員会（委員長：佐地勉）．小児期急性・劇症心筋炎の診断と治療の指針．日小循誌 2006;22: 514-524.
455. 柴田利満，心外膜疾患，高尾篤良，他編．臨床発達心臓病学（改訂3版）．中外医学社，東京 2005: 788-793.
456. Okuda M. A multidisciplinary overview of cardiogenic shock. Shock 2006; 25: 557-570.
457. Peacock WFI, Weber JE. Cardiogenic Shock. In: Tintinalli JE ed. Emergency Medicine. 6 ed. New York, The McGraw-Hill Companies 2004: 242-247.
458. Bell LM. Shock. In: Fleicher GR, Ludwig S eds. Textbook of Pediatric Emergency Medicine. 6 ed. Philadelphia, Lippincott Williamas & Wilkins
2010: 46-57.
459. Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126: e1261-318.
460. Kitamura T, Iwami T, Kawamura T, et al. Conventional and chest-compression-only cardiopulmonary resuscitation by bystanders for children who
have out-of-hospital cardiac arrests: a prospective, nationwide, population-based cohort study. Lancet 2010; 375: 1347-1354.
461. Atkins DL, Everson-Stewart S, Sears GK, et al. Epidemiology and outcomes from out-of-hospital cardiac arrest in children: the Resuscitation
Outcomes Consortium Epistry-Cardiac Arrest. Circulation 2009; 119: 1484-1491.
462. Bardai A, Berdowski J, van der Werf C, et al. Incidence, causes, and outcomes of out-of-hospital cardiac arrest in children. A comprehensive,
prospective, population-based study in the Netherlands. J Am Coll Cardiol 2011; 57: 1822-1828.
463. Berg MD, Schexnayder SM, Chameides L, et al. Part 13: pediatric basic life support: 2010 American Heart Association Guidelines for
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S862-875.
464. Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults.
JAMA 2006; 295: 50-57.
465. Zingarelli B. Shock and reperfusion injury. In: Nichols DGea ed. Roger’s Textbook of Pediatric Intensive Care. 4 ed. Philadelphia, Lippincott Williams
& Wilkins 2008: 252-265.
466. McAneney CM. Basic life support. In: King C, Henretig FM eds. Textbook of Pediatric Emergency Procedures. 2 ed. Philadelphia, Lippincott Williams
& Wilkins 2008: 79-92.
467. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.
Pediatr Crit Care Med 2005; 6: 2-8.
468. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock:
2008. Intensive Care Med 2008; 34: 17-60.
469. 循環器病の診断と治療に関するガイドライン．循環器医のための心肺蘇生・心血管救急に関するガイドライン．Circ J 2009;73, Supple III: 1361-1456.
470. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock:
2008. Crit Care Med 2008; 36: 296-327.
471. Sakr Y, Reinhart K, Vincent JL, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill
Patients (SOAP) Study. Crit Care Med 2006; 34: 589-597.
472. Aschner JL, Poland RL. Sodium bicarbonate: basically useless therapy. Pediatrics 2008; 122: 831-835.
473. Barton P, Garcia J, Kouatli A, et al. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double
-blinded, randomized, placebocontrolled, interventional study. Chest 1996; 109: 1302-1312.
474. Irazuzta JE, Pretzlaff RK, Rowin ME. Amrinone in pediatric refractory septic shock: An open- l abe l pharmacodynamic study. Pediatr Crit Care
Med 2001; 2: 24-28.
475. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers.
BMJ 1998; 317: 235-240.
476. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials.
BMJ 1998; 316: 961-964.
477. Alderson P, Schierhout G, Roberts I, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev
2000: CD000567.
478. Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database
Syst Rev 2002: CD001208.
479. Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:
877-889.
480. Boluyt N, Bollen CW, Bos AP, et al. Fluid resuscitation in neonatal and pediatric hypovolemic shock: a Dutch Pediatric Society evidence-based
clinical practice guideline. Intensive Care Med 2006; 32: 995-1003.
481. Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database
Syst Rev 2004: CD001208.
482. Ceneviva G, Paschall JA, Maffei F, et al. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998; 102: e19.
483. Neumar RW, Nolan JP, Adrie C, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus
statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on
Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of
Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on
Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the
Stroke Council. Circulation 2008; 118: 2452-2483.
484. Branco RG, Garcia PC, Piva JP, et al. Glucose level and risk of mortality in pediatric septic shock. Pediatr Crit Care Med 2005; 6: 470-472.
485. Faustino EV, Apkon M. Persistent hyperglycemia in critically ill children. J Pediatr 2005; 146: 30-34.
486. 麻酔薬および麻酔関連薬使用ガイドライン第3版. http://www.anesth.or.jp/safety/drugs3.html（2012年8月閲覧）
487. Katoh T, Ikeda K. Minimum alveolar concentration of sevoflurane in children. Br J Anaesth 1992; 68: 139-141.
488. Higuchi H, Adachi Y, Wada H, et al. The effect of sevoflurane and isoflurane on renal function in patients with stable moderate renal insufficiency.
Anesth Analg 2001; 92: 650-655.
489. 酒井資之，大隅昭幸，矢野博文，他．イソフルレンの吸収，分解，排泄に関する臨床的研究．麻酔 1987; 36: 1560-1565.
490. 厚生省健康政策局医療技術開発室 監修. 財団法人医療機器センター編. 医療ガス保安管理ハンドブック（改訂版）第4章医療ガス設備・機器. ぎょうせい，
東京 1993. 6393ス設備.
491. Eger EI, Saidman LJ. Minimum alveolar anesthetic concentration: A standard of aestheticpotency. Anesthesiology 1965; 26: 756-763.
492. Baum VC. When nitrous oxide is no laughing matter: nitrous oxide and pediatric anesthesia. Pediatr Anaesth 2007; 17: 824-830.
493. Carton EG, Wanek LA, Housmans PR. Effect of nitrous oxide on contractility, relaxation and the intracellular calcium transient of isolated mammalian
ventricular myocardium. J Pharmacol Exp Ther 1991; 257: 843-849.
494. Smith NT, Eger EI Ⅱ, Stoelting PK, et al. The cardiovascular and sympathomimetic responses to the addition of nitrous oxide to halothane in man.
Anesthesiology 1970; 32: 410-421.
495. Eger EI Ⅱ, Saidman LJ. Hazards of nitrous oxide anesthesia in bowel obstruction and pneumothorax. Anesthesiology 1965; 26: 61-66.
496. Robin R, Seaberg RR, Freeman WR, et al. Permanent postoperative vision loss associated with expansion of intraocular gas in the presence of a
nitrous oxide-containing anesthetic. Anesthesiology 2002; 97: 1309-1310.
497. Eger FI Ⅱ. Uptake of inhaled anesthetics: The alveolar to inspired anesthetic difference; Anesthetic uptake an action. Williams & Wilkins 1974: 77-96.
498. Becker DE, Rosenberg M. Nitrous oxide and the inhalation anesthetics. Anesth Prog 2008; 55: 121-131.
499. Dunn-Russell T, Adair SM, Sams DR, et al. Oxygen saturation and diffusion hypoxia in children following nitrous oxide sedation. Pediatr Dent
1993; 15: 88-92.
500. Gutstein HB, Akil H. Opioid analgesics. In Hardman JG, Limbird LE (eds); Goodman and Guilman’s pharmacological basis of therapeutics, 10th ed.
McGraw-Hill 2001: 569-619.
http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020838s031lbl.pdf (Accessedn on Dec. 31, 2010)
402. Sakarcan A, Tenney F, Wilson JT, et al . The pharmacokinetics of irbesartan in hypertensive children and adolescents. J Clin Pharmacol 2001;
41: 742-749.
403. Wells T, Rippley R, Hogg R, et al. The pharmacokinetics of enalapril in children and infants with hypertension. J Clin Pharmacol 2001; 41: 1064-1074.
404. Hogg RJ, Delucchi A, Sakihara G, et al. A multicenter study of the pharmacokinetics of lisinopril in pediatric patients with hypertension. Pediatr
Nephrol 2007; 22: 695-701.
405. Aronoff GR, Bennet WM, Berns JS, et al. 臨床透析編集委員会編集・翻訳．成人および小児における適正投薬法のガイドライン 腎不全時の薬物使用．
原書第5版．東京，日本メディカルセンター 2007: 242-273.
406. 平田純生，和泉智，古久保拓．透析患者への投薬ガイドブック・慢性腎臓病（CKD）の薬物治療．第2版．東京，じほう 2009.
407. Mclntyre CW, Owen PJ. Prescribing Drugs in Kidney Disease. Brenner BM edits. The Kidney. 8th ed. Philadelphia: Saunders Elsevier: 1930-1952.
408. Bennet WM, Henrich WL, Stoff JS. The renal effects of nonsteroidal anti-inflammatory drugs: summary and recommendations. Am J Kidney Dis
1996; 28 (Suppl 1): S56-62.
409. Blantz RC. Acetaminophen: acute and chronic effects on renal function. Am J Kidney Dis 1996; 28 (Suppl 1): S3-6.
410. 日本腎臓病学会編. CKD診療ガイド 2009. 第2版．東京，東京医学社 2009: 83-113.
411. NSFとガドリニウム造影剤使用に関する合同委員会（日本医学放射線学会, 日本腎臓学会）．腎障害患者におけるガドリニウム造影剤使用に関するガイド
ライン. 2009 年2月．http://www.jsn.or.jp/guideline/
412. Hellden A, Odar-Cederlof I, Stahle L, et al. High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal
failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrol Dial Transplant 2003; 18: 1135-1141.
413. St Peter WL, Redic-Kill KA, Halstenson CE. Clinical pharmacokinetics of antibiotics in patients with impaired renal function. Clin Pharmacokinet
1992; 22: 169-210.
414. 斉藤篤. 腎障害時の化学療法. 外科治療 1997; 72: 1080-1085.
415. 日本感染症学会，日本化学療法学会編．抗菌薬使用のガイドライン．東京，協和企画 2005: 29-33.
416. 田中英高. 患者さんの背景・病態で考える 薬の選び方・使い方のエッセンス. 小児 起立性調節障害. 治療 2009; 91: 1418-1421.
417. Nelson textbook of pediatrics 19th edition 2011.
418. Badesch DB, Abman SH, Ahearn GS, et al. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice
guidelines. Medical therapy for pulmonary arterial hypertension. CHEST 2004; 126: 35S-62S.
419. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulomonary arterial hypertension. Updated ACCP evidence-based clinical practice
guidelines. CHEST 2007; 131: 1917-1928.
420. Fraisse A, Jais X, Schleich JM, et al. Characteristics and prospective 2-year follow-up of children with pulmonary arterial hypertension in France. Arch
Cardiovasc Dis 2010; 103: 66-74.
421. Barst RJ, Ertel SI, Beghetti M, et al. Pulmonary arterial hypertension: a comparison between children and adults. Eur Respir J 2011;37: 665-677.
422. Rubin LJ, Rich S. Primary pulmonary hypertension. Lung biopsy in health and disease Vol.99. Marcel Dekker, Inc., New York 1997: 275-280.
423. Weir EK, Rubin LJ, Ayres SM, et al. The acute administration of vasodilators in primary pulmonary hypertension. Experience from the national
institute of health registry on primary pulmonary hypertension. Am Rev Respir Dis 1989; 140: 1623-1630.
424. Barst RJ, Maislin G, Fishman AP. Vasodilator therapy for primary pulmonary hypertension in children. Circulation 1999; 99: 1197-1208.
425. Roberts DH, Lepore JJ, Maroo A, et al. Oxygen therapy improves cardiac index and pulmonary vascular resistance in patients with pulmonary
hypertension. Chest 2001; 120: 1547-1555.
426. Sitbon O, Brenot F, Denjean A, et al. Inhaled nitric oxide as a screening vasodilator agent in primary pulmonary hypertension. A dose-response
study and comparison with prostacyclin. Am J Respir Crit Care Med 1995; 151: 384-389.
427. Galie N, Humbert M, Vachiery JL, et al. Effects of beraprost sodium, an oral prostacyclin arterial hypertension: A randomized, double-blind, placebo
trial J Am Coll Cardiol 2002; 39: 1496-1502.
428. Barst RJ, McGoon M, McLaughlin V, et al. Beraprost Therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003; 41: 2119-2125.
429. Yung D, Widlitz AC, Rosenzweig EB, et al. Outcome in children with idiopathic pulmonary arterial hypertension. Circulation 2004; 110: 660-665.
430. Maiya S, Hislop AA, Flynn Y, et al. Response to bosentan in children with pulmonary hypertension. Heart 2006; 92: 664-670.
431. Beghtti M, Hoeper MM, Kiely DG, et al. Safety experience with bosentan in 146 children 2-11 years old with pulmonary arterial hypertension: Result
from the Europe an postmarketing surveillance program. Pediatr Res 2008; 64: 200-204.
432. Paul GA, Gibbs JSR, Boobis AR, et al. Bosentan decreases the plasma concentration of sildenafil when coprescribed in pulmonary hypertension.
Br J Clin Pharmacol 2005; 60: 107-112.
433. Barst RJ, Ivy DD, Gaitan G, et al. A randomized, doubleblind, placebo-controlled, dose-ranging study of oral sildenafil citrare citrate in treatment-naïve
children with pulmonary hypertension. Circulation 2012; 125: 324-334.
434. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 2005; 353: 2148-2157.
435. Namachivayam P, Theilen U, Butt WW, et al. Sildenafil prevents rebound pulmonary hypertension after withdrawal of nitric oxide in children. Am
J Respir Crit Care Med; 2006: 1042-1047.
436. Nagendran J, Archer SL, Soliman D, et al. PDE5 is highly expressed in the hypertrophied human right ventricle and acute inhibition of PDE5 improves
contractility. Circulation 2007; 116: 238-248.
437. Sitbon O, Rubin LJ, Long WA, et al. Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. Circulation , 2005;
111: 3105-3111.
438. Richardson P, McKenna W, Bristow M, et al. Report of the 1995 World Health Organization/International Society and Federation of Cardiology task
force on the definition and classification of cardiomyopathies. Circulation 1996; 93: 841-842.
439. 市田蕗子，佐地勉，梶野浩樹，他．平成21年度希少疾病サーベイランス調査結果．日小循誌 2010; 26: 348-350.
440. Heersche JH, Blom NA, Van de Heuvel F, et al. Implantable Cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the
Netherlands. Pacing Clin Electrophysiol 2009; 33: 179-185.
441. Melacini P, Maron BJ, Bobbo F, et al. Evidence that pharmacological strategies lack efficacy for the prevention of sudden death in hypertrophic
cardiomyopathy. Heart 2007; 93: 708-710.
442. Fidler LM, Wilson GJ, Liu F, et al. Abnormal connexin43 in arrhythmogenic right ventricular cardiomyopathy caused by plakophilin-2 mutations. J Cell
Mol Med 2009; 13: 4219-4228.
443. The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
444. Pasquali SK, Hall M, Slonim AD, et al. Off-label use of cardiovascular medications in children hospitalized with congenital and acquired heart disease.
Circ Cardiovasc Qual Outcomes 2008; 1: 74-83.
445. Venugopalan P, Agarwal AK, Worthing EA. Chronic cardiac failure in children due to dilated cardiomyopathy: diagnostic approach, pathophysiology
and management. Eur J Pediatr 2000; 159: 803-810.
446. Shaddy RE, Boucek MM, Hsu DT, et al. Pediatric Carvedilol Study Group, Carvedilol for children and adlescents with heart failure: a randomised
controlled trial. JAMA 2007; 298: 1171-1179.
447. Cochrane Database of Systematic Reviews. Beta-blockers for congestive heart failure in children. 1, 2009.
448. Amiodarone Trials Meta-Analysis Investigators. Effect of prophylactic amiodarone on mortality after acute myocardial infarction and in congestive heart
failure: meta-analysis of individual data from 6500 patients in ramdomised trials. Lancet 1997; 350: 1417-1424.
449. 住友直方，岩本眞理，牛ノ濱大地，他．小児循環器学会「小児不整脈の診断・治療に関する検討委員会」．小児不整脈の診断・治療ガイドライン．日小循誌
2010, supple.
450. Ostman-Smith I. Hypertrophic cardiomyopathy in childhood and adolescence - strategies to prevent sudden death. Fund & Clin Pharmacol 2010;
24: 637-652.
451. Duncan WJ, Tyrrell MJ, Bharadwal BB. Disopyramide as a negative inotrope in obstructive cardiomyopathy in children. Can J Cardiol 1991; 7: 81-86.
452. Klugman D, Berger JT, Sable CA, et al. Pediatric patients hospitalized with myocarditis: a multi-institutional analysis. Pediatr Cardiol 2010; 31:
222-228.
453. Drucker NA, Drucker NA, Colan SD, et al. Gammaglobulin treatment of acute myocarditis in the pediatric population. Circulation 1994; 89: 252-257.
454. 日本小児循環器学会学術委員会（委員長：佐地勉）．小児期急性・劇症心筋炎の診断と治療の指針．日小循誌 2006;22: 514-524.
455. 柴田利満，心外膜疾患，高尾篤良，他編．臨床発達心臓病学（改訂3版）．中外医学社，東京 2005: 788-793.
456. Okuda M. A multidisciplinary overview of cardiogenic shock. Shock 2006; 25: 557-570.
457. Peacock WFI, Weber JE. Cardiogenic Shock. In: Tintinalli JE ed. Emergency Medicine. 6 ed. New York, The McGraw-Hill Companies 2004: 242-247.
458. Bell LM. Shock. In: Fleicher GR, Ludwig S eds. Textbook of Pediatric Emergency Medicine. 6 ed. Philadelphia, Lippincott Williamas & Wilkins
2010: 46-57.
459. Kleinman ME, de Caen AR, Chameides L, et al. Pediatric basic and advanced life support: 2010 International Consensus on Cardiopulmonary
Resuscitation and Emergency Cardiovascular Care Science with Treatment Recommendations. Pediatrics 2010; 126: e1261-318.
460. Kitamura T, Iwami T, Kawamura T, et al. Conventional and chest-compression-only cardiopulmonary resuscitation by bystanders for children who
have out-of-hospital cardiac arrests: a prospective, nationwide, population-based cohort study. Lancet 2010; 375: 1347-1354.
461. Atkins DL, Everson-Stewart S, Sears GK, et al. Epidemiology and outcomes from out-of-hospital cardiac arrest in children: the Resuscitation
Outcomes Consortium Epistry-Cardiac Arrest. Circulation 2009; 119: 1484-1491.
462. Bardai A, Berdowski J, van der Werf C, et al. Incidence, causes, and outcomes of out-of-hospital cardiac arrest in children. A comprehensive,
prospective, population-based study in the Netherlands. J Am Coll Cardiol 2011; 57: 1822-1828.
463. Berg MD, Schexnayder SM, Chameides L, et al. Part 13: pediatric basic life support: 2010 American Heart Association Guidelines for
Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010; 122: S862-875.
464. Nadkarni VM, Larkin GL, Peberdy MA, et al. First documented rhythm and clinical outcome from in-hospital cardiac arrest among children and adults.
JAMA 2006; 295: 50-57.
465. Zingarelli B. Shock and reperfusion injury. In: Nichols DGea ed. Roger’s Textbook of Pediatric Intensive Care. 4 ed. Philadelphia, Lippincott Williams
& Wilkins 2008: 252-265.
466. McAneney CM. Basic life support. In: King C, Henretig FM eds. Textbook of Pediatric Emergency Procedures. 2 ed. Philadelphia, Lippincott Williams
& Wilkins 2008: 79-92.
467. Goldstein B, Giroir B, Randolph A. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics.
Pediatr Crit Care Med 2005; 6: 2-8.
468. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock:
2008. Intensive Care Med 2008; 34: 17-60.
469. 循環器病の診断と治療に関するガイドライン．循環器医のための心肺蘇生・心血管救急に関するガイドライン．Circ J 2009;73, Supple III: 1361-1456.
470. Dellinger RP, Levy MM, Carlet JM, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock:
2008. Crit Care Med 2008; 36: 296-327.
471. Sakr Y, Reinhart K, Vincent JL, et al. Does dopamine administration in shock influence outcome? Results of the Sepsis Occurrence in Acutely Ill
Patients (SOAP) Study. Crit Care Med 2006; 34: 589-597.
472. Aschner JL, Poland RL. Sodium bicarbonate: basically useless therapy. Pediatrics 2008; 122: 831-835.
473. Barton P, Garcia J, Kouatli A, et al. Hemodynamic effects of i.v. milrinone lactate in pediatric patients with septic shock. A prospective, double
-blinded, randomized, placebocontrolled, interventional study. Chest 1996; 109: 1302-1312.
474. Irazuzta JE, Pretzlaff RK, Rowin ME. Amrinone in pediatric refractory septic shock: An open- l abe l pharmacodynamic study. Pediatr Crit Care
Med 2001; 2: 24-28.
475. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. Cochrane Injuries Group Albumin Reviewers.
BMJ 1998; 317: 235-240.
476. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials.
BMJ 1998; 316: 961-964.
477. Alderson P, Schierhout G, Roberts I, et al. Colloids versus crystalloids for fluid resuscitation in critically ill patients. Cochrane Database Syst Rev
2000: CD000567.
478. Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database
Syst Rev 2002: CD001208.
479. Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:
877-889.
480. Boluyt N, Bollen CW, Bos AP, et al. Fluid resuscitation in neonatal and pediatric hypovolemic shock: a Dutch Pediatric Society evidence-based
clinical practice guideline. Intensive Care Med 2006; 32: 995-1003.
481. Alderson P, Bunn F, Lefebvre C, et al. Human albumin solution for resuscitation and volume expansion in critically ill patients. Cochrane Database
Syst Rev 2004: CD001208.
482. Ceneviva G, Paschall JA, Maffei F, et al. Hemodynamic support in fluid-refractory pediatric septic shock. Pediatrics 1998; 102: e19.
483. Neumar RW, Nolan JP, Adrie C, et al. Post-cardiac arrest syndrome: epidemiology, pathophysiology, treatment, and prognostication. A consensus
statement from the International Liaison Committee on Resuscitation (American Heart Association, Australian and New Zealand Council on
Resuscitation, European Resuscitation Council, Heart and Stroke Foundation of Canada, InterAmerican Heart Foundation, Resuscitation Council of
Asia, and the Resuscitation Council of Southern Africa); the American Heart Association Emergency Cardiovascular Care Committee; the Council on
Cardiovascular Surgery and Anesthesia; the Council on Cardiopulmonary, Perioperative, and Critical Care; the Council on Clinical Cardiology; and the
Stroke Council. Circulation 2008; 118: 2452-2483.
484. Branco RG, Garcia PC, Piva JP, et al. Glucose level and risk of mortality in pediatric septic shock. Pediatr Crit Care Med 2005; 6: 470-472.
485. Faustino EV, Apkon M. Persistent hyperglycemia in critically ill children. J Pediatr 2005; 146: 30-34.
486. 麻酔薬および麻酔関連薬使用ガイドライン第3版. http://www.anesth.or.jp/safety/drugs3.html（2012年8月閲覧）
487. Katoh T, Ikeda K. Minimum alveolar concentration of sevoflurane in children. Br J Anaesth 1992; 68: 139-141.
488. Higuchi H, Adachi Y, Wada H, et al. The effect of sevoflurane and isoflurane on renal function in patients with stable moderate renal insufficiency.
Anesth Analg 2001; 92: 650-655.
489. 酒井資之，大隅昭幸，矢野博文，他．イソフルレンの吸収，分解，排泄に関する臨床的研究．麻酔 1987; 36: 1560-1565.
490. 厚生省健康政策局医療技術開発室 監修. 財団法人医療機器センター編. 医療ガス保安管理ハンドブック（改訂版）第4章医療ガス設備・機器. ぎょうせい，
東京 1993. 6393ス設備.
491. Eger EI, Saidman LJ. Minimum alveolar anesthetic concentration: A standard of aestheticpotency. Anesthesiology 1965; 26: 756-763.
492. Baum VC. When nitrous oxide is no laughing matter: nitrous oxide and pediatric anesthesia. Pediatr Anaesth 2007; 17: 824-830.
493. Carton EG, Wanek LA, Housmans PR. Effect of nitrous oxide on contractility, relaxation and the intracellular calcium transient of isolated mammalian
ventricular myocardium. J Pharmacol Exp Ther 1991; 257: 843-849.
494. Smith NT, Eger EI Ⅱ, Stoelting PK, et al. The cardiovascular and sympathomimetic responses to the addition of nitrous oxide to halothane in man.
Anesthesiology 1970; 32: 410-421.
495. Eger EI Ⅱ, Saidman LJ. Hazards of nitrous oxide anesthesia in bowel obstruction and pneumothorax. Anesthesiology 1965; 26: 61-66.
496. Robin R, Seaberg RR, Freeman WR, et al. Permanent postoperative vision loss associated with expansion of intraocular gas in the presence of a
nitrous oxide-containing anesthetic. Anesthesiology 2002; 97: 1309-1310.
497. Eger FI Ⅱ. Uptake of inhaled anesthetics: The alveolar to inspired anesthetic difference; Anesthetic uptake an action. Williams & Wilkins 1974: 77-96.
498. Becker DE, Rosenberg M. Nitrous oxide and the inhalation anesthetics. Anesth Prog 2008; 55: 121-131.
499. Dunn-Russell T, Adair SM, Sams DR, et al. Oxygen saturation and diffusion hypoxia in children following nitrous oxide sedation. Pediatr Dent
1993; 15: 88-92.
500. Gutstein HB, Akil H. Opioid analgesics. In Hardman JG, Limbird LE (eds); Goodman and Guilman’s pharmacological basis of therapeutics, 10th ed.
McGraw-Hill 2001: 569-619.
小児期心疾患における薬物療法ガイドライン
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）
Guidelines for Drug Therapy in Pediatric Patients with Cardiovascular Diseases （ JCS2012）